使用阿柏西普治疗新生血管性年龄相关性黄斑变性的改良观察与计划方案。 - Suppr | 超能文献

Modified observe-and-plan regimen using aflibercept for neovascular age-related macular degeneration.

作者信息

Jeong Seongyong, Ryu Gahyung, Sagong Min

机构信息

Department of Ophthalmology, Yeungnam University College of Medicine, Daegu, Korea.

Yeungnam Eye Center, Yeungnam University Hospital, Daegu, Korea.

出版信息

Acta Ophthalmol. 2021 Dec;99(8):e1535-e1536. doi: 10.1111/aos.14803. Epub 2021 Mar 26.

DOI:10.1111/aos.14803

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Modified observe-and-plan regimen using aflibercept for neovascular age-related macular degeneration.使用阿柏西普治疗新生血管性年龄相关性黄斑变性的改良观察与计划方案。

Acta Ophthalmol. 2021 Dec;99(8):e1535-e1536. doi: 10.1111/aos.14803. Epub 2021 Mar 26.

2

INTRAVITREAL ZIV-AFLIBERCEPT FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: 52-Week Results.玻璃体内注射 ZIV-AFLIBERCEPT 治疗新生血管性年龄相关性黄斑变性：52 周结果。

Retina. 2019 Apr;39(4):648-655. doi: 10.1097/IAE.0000000000002001.

3

INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.抗血管内皮生长因子治疗新生血管性年龄相关性黄斑变性后视网膜色素上皮撕裂的发生率和长期视力结局。

Retina. 2019 Apr;39(4):664-669. doi: 10.1097/IAE.0000000000002029.

4

Intravitreal aflibercept efficacy in neovascular age-related macular degeneration with suboptimal response to anti-vascular endothelial growth factor-A therapy.玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性对抗血管内皮生长因子-A治疗反应欠佳的疗效

Eur J Ophthalmol. 2020 Sep;30(5):1082-1090. doi: 10.1177/1120672119848961. Epub 2019 May 14.

5

Macular Atrophy in Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial Comparing Ranibizumab and Aflibercept (RIVAL Study).新生血管性年龄相关性黄斑变性的黄斑萎缩：比较雷珠单抗和阿柏西普的随机临床试验（RIVAL 研究）。

Ophthalmology. 2020 Feb;127(2):198-210. doi: 10.1016/j.ophtha.2019.08.023. Epub 2019 Aug 27.

6

Real-world 10-year experiences with intravitreal treatment with ranibizumab and aflibercept for neovascular age-related macular degeneration.抗 VEGF 药物治疗新生血管性年龄相关性黄斑变性的 10 年真实世界临床经验。

Acta Ophthalmol. 2020 Mar;98(2):132-138. doi: 10.1111/aos.14183. Epub 2019 Jul 8.

7

EYLEA as First-line Treatment in Wet Age-related Macular Degeneration: An Expert Panel Discussion.阿柏西普作为湿性年龄相关性黄斑变性的一线治疗：专家小组讨论

Retina. 2021 Jun 1;41(Suppl 1):S1-S8. doi: 10.1097/01.iae.0000754904.61893.77.

8

Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.阿柏西普治疗新生血管性年龄相关性黄斑变性的中心凹下脉络膜厚度：12 个月结果。

Ophthalmology. 2016 Mar;123(3):617-24. doi: 10.1016/j.ophtha.2015.10.039. Epub 2015 Dec 11.

9

Predicting visual outcomes in patients treated with aflibercept for neovascular age-related macular degeneration: Data from a real-world clinical setting.预测阿柏西普治疗新生血管性年龄相关性黄斑变性患者的视力预后：来自真实临床环境的数据。

Eur J Ophthalmol. 2020 May;30(3):543-549. doi: 10.1177/1120672119839299. Epub 2019 Apr 2.

10

Intravitreal Combined Aflibercept + Anti-Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.玻璃体内联合应用阿柏西普+抗血小板衍生生长因子受体 β 治疗新生血管性年龄相关性黄斑变性：2 期 CAPELLA 试验结果。

Ophthalmology. 2020 Feb;127(2):211-220. doi: 10.1016/j.ophtha.2019.09.021. Epub 2019 Sep 25.

引用本文的文献

1

Two-year Outcomes of Intravitreal Aflibercept Injection for Neovascular Age-related Macular Degeneration with "Observe before Treat-and-Extend" Method.“观察等待-治疗-再延长”方案下玻璃体内注射阿柏西普治疗新生血管性年龄相关性黄斑变性的两年疗效观察。

Korean J Ophthalmol. 2024 Oct;38(5):380-391. doi: 10.3341/kjo.2024.0083. Epub 2024 Aug 20.